Minapharm Pharmaceuticals (CAI:MIPH) EV-to-EBIT : 36.46 (As of May. 29, 2025)

Minapharm Pharmaceuticals EV-to-EBIT Chart

Competitive Comparison of Minapharm Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minapharm Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's EV-to-EBIT falls into.

Minapharm Pharmaceuticals EV-to-EBIT Calculation

Minapharm Pharmaceuticals's EV-to-EBIT for today is calculated as:

Minapharm Pharmaceuticals's current Enterprise Value is E£8,473 Mil.
Minapharm Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£232 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals  (CAI:MIPH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Minapharm Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 was E£7,454 Mil.
Minapharm Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was E£232 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Minapharm Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Minapharm Pharmaceuticals Business Description